- Home
- NFBK vs INBX Comparison
NFBK vs INBX Comparison
Compare NFBK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- INBX
- Stock Information
- Founded
- NFBK 1887
- INBX 2010
- Country
- NFBK United States
- INBX United States
- Employees
- NFBK N/A
- INBX N/A
- Industry
- NFBK Major Banks
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- INBX Health Care
- Exchange
- NFBK Nasdaq
- INBX Nasdaq
- Market Cap
- NFBK 454.5M
- INBX 430.2M
- IPO Year
- NFBK 2007
- INBX 2020
- Fundamental
- Price
- NFBK $10.00
- INBX $80.98
- Analyst Decision
- NFBK Hold
- INBX Hold
- Analyst Count
- NFBK 3
- INBX 2
- Target Price
- NFBK $12.67
- INBX N/A
- AVG Volume (30 Days)
- NFBK 192.0K
- INBX 734.6K
- Earning Date
- NFBK 10-22-2025
- INBX 11-14-2025
- Dividend Yield
- NFBK 5.08%
- INBX N/A
- EPS Growth
- NFBK 51.92
- INBX N/A
- EPS
- NFBK 0.97
- INBX N/A
- Revenue
- NFBK $141,983,000.00
- INBX $1,400,000.00
- Revenue This Year
- NFBK $9.42
- INBX $563.00
- Revenue Next Year
- NFBK $7.14
- INBX $230.77
- P/E Ratio
- NFBK $10.53
- INBX N/A
- Revenue Growth
- NFBK 13.99
- INBX N/A
- 52 Week Low
- NFBK $9.40
- INBX $10.81
- 52 Week High
- NFBK $14.39
- INBX $86.64
- Technical
- Relative Strength Index (RSI)
- NFBK 32.36
- INBX 82.88
- Support Level
- NFBK $10.00
- INBX $28.16
- Resistance Level
- NFBK $10.25
- INBX $86.62
- Average True Range (ATR)
- NFBK 0.29
- INBX 7.65
- MACD
- NFBK -0.05
- INBX 2.94
- Stochastic Oscillator
- NFBK 1.97
- INBX 90.44
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.